Dodecyltrimethylammonium
Star0
Identification
- Generic Name
- Dodecyltrimethylammonium
- DrugBank Accession Number
- DB02779
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 228.4372
Monoisotopic: 228.269125093 - Chemical Formula
- C15H34N
- Synonyms
- Dodecane-trimethylamine
- Dodecyl-trimethyl-azanium
- Dodecyltrimethylammonium ion
- laurtrimonium
- laurtrimonium cation
- laurtrimonium ion
- n-Dodecyltrimethylammonium
- N,N,N-Trimethyl-1-dodecanaminium
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UTyrosine-protein phosphatase non-receptor type 11 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key laurtrimonium bromide 6IC8NZ97S2 1119-94-4 Not applicable
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tetraalkylammonium salts. These are organonitrogen compounds containing a quaternary ammonium substituted with four alkyl chains.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Quaternary ammonium salts
- Direct Parent
- Tetraalkylammonium salts
- Alternative Parents
- Organopnictogen compounds / Organic salts / Hydrocarbon derivatives / Amines / Organic cations
- Substituents
- Aliphatic acyclic compound / Amine / Hydrocarbon derivative / Organic cation / Organic salt / Organopnictogen compound / Tetraalkylammonium salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- quaternary ammonium ion (CHEBI:41378)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GT3793XV5S
- CAS number
- 10182-91-9
- InChI Key
- VICYBMUVWHJEFT-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H34N/c1-5-6-7-8-9-10-11-12-13-14-15-16(2,3)4/h5-15H2,1-4H3/q+1
- IUPAC Name
- dodecyltrimethylazanium
- SMILES
- CCCCCCCCCCCC[N+](C)(C)C
References
- General References
- Not Available
- External Links
- PubChem Compound
- 8153
- PubChem Substance
- 46506419
- ChemSpider
- 7861
- BindingDB
- 50060599
- ChEBI
- 41378
- ChEMBL
- CHEMBL1180004
- ZINC
- ZINC000001673414
- PharmGKB
- PA451988
- PDBe Ligand
- CAT
- PDB Entries
- 2shp / 4ib7 / 4ib9 / 6he6
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 2 Unknown Status Treatment Local Anaesthesia therapy / Wounds Injuries 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.17e-05 mg/mL ALOGPS logP 1.26 ALOGPS logP 0.91 Chemaxon logS -7.4 ALOGPS Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 86.58 m3·mol-1 Chemaxon Polarizability 32.51 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8956 Blood Brain Barrier + 0.9693 Caco-2 permeable + 0.7014 P-glycoprotein substrate Non-substrate 0.5098 P-glycoprotein inhibitor I Non-inhibitor 0.9556 P-glycoprotein inhibitor II Non-inhibitor 0.7862 Renal organic cation transporter Non-inhibitor 0.6184 CYP450 2C9 substrate Non-substrate 0.8557 CYP450 2D6 substrate Non-substrate 0.6596 CYP450 3A4 substrate Substrate 0.5059 CYP450 1A2 substrate Non-inhibitor 0.8243 CYP450 2C9 inhibitor Non-inhibitor 0.947 CYP450 2D6 inhibitor Non-inhibitor 0.9149 CYP450 2C19 inhibitor Non-inhibitor 0.9266 CYP450 3A4 inhibitor Non-inhibitor 0.9831 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9722 Ames test Non AMES toxic 0.9617 Carcinogenicity Carcinogens 0.7243 Biodegradation Ready biodegradable 0.8286 Rat acute toxicity 2.8455 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8233 hERG inhibition (predictor II) Non-inhibitor 0.5139
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0a4i-8900000000-94642fbc38179546fd05 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 159.66382 predictedDeepCCS 1.0 (2019) [M+H]+ 163.52821 predictedDeepCCS 1.0 (2019) [M+Na]+ 172.76872 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Sh3/sh2 adaptor activity
- Specific Function
- Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Dephosphorylates ROCK2 at Tyr-722 result...
- Gene Name
- PTPN11
- Uniprot ID
- Q06124
- Uniprot Name
- Tyrosine-protein phosphatase non-receptor type 11
- Molecular Weight
- 68436.0 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at December 13, 2022 10:46